GH1 and cancer: A range of risk factors for MetS among cancer survivors has been reported, including local cancer treatment (surgery and radiotherapy), general cancer treatment (chemotherapy and endocrinotherapy), hormonal changes (growth hormone, thyroid hormone, and deficiency of testosterone), metabolic imbalances, sympathetic nervous system changes, and health-related lifestyle choices (physical activity, diet, and smoking) [11–13].